JP2019501190A - Ｄｇｌａを含む薬学的組成物及びその使用 - Google Patents

Ｄｇｌａを含む薬学的組成物及びその使用 Download PDF

Info

Publication number
JP2019501190A
JP2019501190A JP2018535278A JP2018535278A JP2019501190A JP 2019501190 A JP2019501190 A JP 2019501190A JP 2018535278 A JP2018535278 A JP 2018535278A JP 2018535278 A JP2018535278 A JP 2018535278A JP 2019501190 A JP2019501190 A JP 2019501190A
Authority
JP
Japan
Prior art keywords
dgla
subject
disease
baseline
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018535278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501190A5 (enExample
Inventor
ドゥンネ ジェームス
ドゥンネ ジェームス
マンク メハル
マンク メハル
クリマク ジョン
クリマク ジョン
コウグフラン デビッド
コウグフラン デビッド
Original Assignee
ディーエス バイオファーマ リミテッド
ディーエス バイオファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディーエス バイオファーマ リミテッド, ディーエス バイオファーマ リミテッド filed Critical ディーエス バイオファーマ リミテッド
Publication of JP2019501190A publication Critical patent/JP2019501190A/ja
Publication of JP2019501190A5 publication Critical patent/JP2019501190A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018535278A 2016-01-07 2017-01-06 Ｄｇｌａを含む薬学的組成物及びその使用 Pending JP2019501190A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276019P 2016-01-07 2016-01-07
US62/276,019 2016-01-07
US201662357000P 2016-06-30 2016-06-30
US62/357,000 2016-06-30
PCT/IB2017/000066 WO2017118911A1 (en) 2016-01-07 2017-01-06 Pharmaceutical compositions comprising dgla and use of same

Publications (2)

Publication Number Publication Date
JP2019501190A true JP2019501190A (ja) 2019-01-17
JP2019501190A5 JP2019501190A5 (enExample) 2020-02-13

Family

ID=58213263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535278A Pending JP2019501190A (ja) 2016-01-07 2017-01-06 Ｄｇｌａを含む薬学的組成物及びその使用

Country Status (6)

Country Link
US (2) US20170196825A1 (enExample)
EP (1) EP3399971A1 (enExample)
JP (1) JP2019501190A (enExample)
CN (1) CN108778266A (enExample)
CA (1) CA3027867A1 (enExample)
WO (1) WO2017118911A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2015071766A1 (en) 2013-11-15 2015-05-21 Dignity Sciences Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
AU2015270418B2 (en) 2014-06-04 2020-08-06 Ds Biopharma Limited Pharmaceutical compositions comprising DGLA and use of same
EP3294282A1 (en) 2015-05-13 2018-03-21 DS Biopharma Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
MA49148A (fr) * 2017-05-19 2020-03-25 Ds Biopharma Ltd Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
US10639313B2 (en) 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152324A (ja) * 1983-02-01 1984-08-31 エフア−モル・リミテツド 医薬または健康食品組成物
JP2006219454A (ja) * 2005-02-14 2006-08-24 Suntory Ltd 皮膚疾患経口治療または予防剤
WO2015185698A1 (en) * 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006287B2 (en) * 2005-02-14 2015-04-14 Suntory Holdings Limited Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152324A (ja) * 1983-02-01 1984-08-31 エフア−モル・リミテツド 医薬または健康食品組成物
JP2006219454A (ja) * 2005-02-14 2006-08-24 Suntory Ltd 皮膚疾患経口治療または予防剤
WO2015185698A1 (en) * 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Also Published As

Publication number Publication date
WO2017118911A1 (en) 2017-07-13
CN108778266A (zh) 2018-11-09
EP3399971A1 (en) 2018-11-14
US20170196825A1 (en) 2017-07-13
CA3027867A1 (en) 2017-07-13
US20190175534A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
JP2019501190A (ja) Ｄｇｌａを含む薬学的組成物及びその使用
US10849870B2 (en) Pharmaceutical compositions comprising DGLA and use of same
CN104582698A (zh) 在接受抑制素治疗的受试者中降低心血管事件风险的方法
JP2018515460A (ja) 炎症または神経障害性疼痛を処置する方法
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
EP4342475A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
JP2020520938A (ja) Ｄｇｌａを含む薬学的組成物およびその使用
HK40034640A (en) Pharmaceutical compositions comprising dgla and use of same
HK1236390B (en) Pharmaceutical compositions comprising dgla and use of same
HK1236390A1 (en) Pharmaceutical compositions comprising dgla and use of same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210511